ACID REDUCER 150 MG
RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG · DIN 02296160 · APOTEX INC
Health Canada status: DORMANT
What is ACID REDUCER?
ACID REDUCER 150 MG contains RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02296160, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as dormant, status dated 31-Jul-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACID REDUCER used for?
Fast and effective relief, treatment, and prevention of acid indigestion (dyspepsia), heartburn, hyperacidity, sour stomach, and upset stomach associated with excess stomach acid.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02296160 |
|---|---|
| Brand name | ACID REDUCER |
| Generic / active ingredient | RANITIDINE (RANITIDINE HYDROCHLORIDE) : 150 MG |
| Manufacturer | APOTEX INC |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | A02BA02 RANITIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 31-Jul-2020 |
| Original market date | 2014-03-20 00:00:00 |
How is it administered?
Adults/Children 16+: 1 tablet when symptoms appear. If symptoms persist/return after 1 hour, take a second. Prevention: 1 tablet 30-60 mins before eating. Max 2 tablets in 24 hours. Swallow whole.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (refers to Storage and Stability section).
How is it supplied?
Not explicitly detailed in provided text (refers to Dosage Forms, Composition and Packaging section).
Contraindications
Known hypersensitivity to any component of the preparation or history of hypersensitivity to other histamine H2-receptor antagonists.
Warnings and precautions
May mask symptoms of stomach carcinoma. Avoid in patients with history of acute porphyria. Increased risk of pneumonia in elderly/immunocompromised. Caution when driving if dizzy/drowsy.
What can be used instead?
Other Canadian products sharing ATC code A02BA02 RANITIDINE. 5 of 96 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAR-RANITIDINE | 150 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443708 |
| MAR-RANITIDINE | 300 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02443716 |
| MAXIMUM STRENGTH ACID REDUCER WITHOUT PRESCRIPTION | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02293471 |
| MINT-RANITIDINE | 150 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526379 |
| MINT-RANITIDINE | 300 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02526387 |
| ACID REDUCER | 150 MG | TABLET | PENDOPHARM DIVISION OF PHARMASCIENCE INC | APPROVED | DIN 02291282 |
| ACID REDUCER | 150 MG | TABLET | PHARMASCIENCE INC | CANCELLED POST MARKET | DIN 02400103 |
| ACID REDUCER | 75 MG | TABLET | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | DIN 02237829 |
| ACID REDUCER | 75 MG | TABLET | APOTEX INC | DORMANT | DIN 02230507 |
| ACID REDUCER | 75 MG | TABLET | VITA HEALTH PRODUCTS INC | DORMANT | DIN 02298740 |
Who else supplies RANITIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. RANITIDINE appears in 4061 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.